EMCURE vs INDSWFTLAB: Stock Comparison
Emcure Pharmaceuticals Limited vs Ind-Swift Laboratories Limited
Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings
Emcure Pharmaceuticals Limited is the larger company by market capitalisation. Emcure Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Ind-Swift Laboratories Limited shows lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Emcure Pharmaceuticals Limited and Ind-Swift Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| Live Price | ₹1,893.9 | ₹234.31 |
| Day Change | -1.59% | -1.38% |
| Volume | 93,963 | 3.77 L |
| 52-Week High | ₹1,944 | ₹248.45 |
| 52-Week Low | ₹1,260 | ₹87.15 |
| Distance from 52W High | -2.58% | -5.69% |
Valuation
| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| Market Cap | ₹35,904 Cr | ₹2,035 Cr |
| P/E Ratio | 39.68x | 50.25x |
| P/B Ratio | 7.41x | 1.5x |
| EPS | ₹48.76 | ₹4.84 |
| Book Value | ₹261.12 | ₹165.77 |
| Dividend Yield | 0.16% | 0% |
Growth
| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 16.7% | -66.6% |
| EPS Growth (TTM YoY) | 28.8% | -94.8% |
| Qtr Sales Growth | 16.7% | 22.8% |
| Qtr Profit Growth | 21% | 9.35% |
Profitability & Leverage
| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| ROE | 20.1% | 3.87% |
| ROCE | 24% | 4.7% |
| Net Margin | 10.04% | 41.4% |
| Operating Margin | 20.3% | 7.03% |
| Debt to Equity | 0.31x | 0.01x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | EMCURE | INDSWFTLAB |
|---|---|---|
| Promoter Holding | 77.64%▼ 0.01 pp | 42.99%▲ 3.49 pp |
| FII Holding | 3.35%▼ 0.24 pp | 13.88%▼ 0.45 pp |
| DII Holding | 6.1% | 0%▼ 0.68 pp |
| Public Holding | 12.68%▲ 0.24 pp | 43.12%▼ 2.38 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Emcure Pharmaceuticals Limited and Ind-Swift Laboratories Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.